PHARMABEES
Nippon AMC - NETF Pharma
Each stock's 10,000-path forecast, rendered as light.
Nippon AMC - NETF Pharma (PHARMABEES) Stock Analysis & Case Study
Is PHARMABEES a good buy? The data-driven verdict.
on the numbers it worth a closer look, a Downstox Snapshot Score of 61/100.
On the numbers, Nippon AMC - NETF Pharma (PHARMABEES) worth a closer look, a Downstox Snapshot Score of 61/100, weighing a 77% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
PHARMABEES share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 1.9y of PHARMABEES history (13%/yr drift, 15%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| PHARMABEES 2027 | ₹23 | ₹29 | ₹35 | +12% |
| PHARMABEES 2028 | ₹24 | ₹32 | ₹42 | +26% |
| PHARMABEES 2029 | ₹25 | ₹36 | ₹50 | +41% |
| PHARMABEES 2030 | ₹27 | ₹40 | ₹59 | +58% |
| PHARMABEES 2031 | ₹29 | ₹45 | ₹70 | +77% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability PHARMABEES goes up, or doubles?
The bull case for PHARMABEES
- A 10,000-path probability model puts a 77% chance the price is higher in a year, with a median target of ₹29 (+12%).
- Relatively low volatility (15%/yr), a steadier ride than the typical mid/small-cap.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹50.
The bear case & risks
- No model or past record guarantees future returns, treat this as one input, not a decision.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹25.
PHARMABEES volatility & expected range, how bumpy is the ride?
Over the last 1.9 years PHARMABEES compounded at 13%/year with annualized volatility of 15%. That volatility implies a 1-year 80% range of ₹23–₹35, the honest backbone behind any single price target.
PHARMABEES price forecast, the full 60-month probability fan
PHARMABEES price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds PHARMABEES hits common targets within the simulated horizon?
Full multi-horizon detail on the PHARMABEES price target & forecast page.
PHARMABEES MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy PHARMABEES with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 26.5% | 3.8× |
| ZerodhaCHEAPEST | 26.5% | 3.8× |
| DhanCHEAPEST | 26.5% | 3.8× |
Compare every broker on the PHARMABEES MTF page.
PHARMABEES vs peers,sector comparison
About Nippon AMC - NETF Pharma: sector, index & market-cap context
Nippon AMC - NETF Pharma (PHARMABEES) is an NSE-listed company.
How the PHARMABEES Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Nippon AMC - NETF Pharma's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
PHARMABEES analysis, FAQs
Is Nippon AMC - NETF Pharma (PHARMABEES) a good buy?
On the numbers, Nippon AMC - NETF Pharma (PHARMABEES) worth a closer look, a Downstox Snapshot Score of 61/100, weighing a 77% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is PHARMABEES overvalued or undervalued?
Valuation ratios for PHARMABEES are tracked live on Downstox.
What is the PHARMABEES share price target for 2031?
PHARMABEES's probability-weighted 2031 median target is ₹45, with an 80% range of ₹29–₹70 (10,000-path Monte-Carlo).
What is the probability PHARMABEES doubles in 5 years?
The modelled probability of PHARMABEES reaching ₹51 (2×) within 5 years is 36%.
What is the bull case for PHARMABEES?
A 10,000-path probability model puts a 77% chance the price is higher in a year, with a median target of ₹29 (+12%). Relatively low volatility (15%/yr), a steadier ride than the typical mid/small-cap.
What are the risks in PHARMABEES?
No model or past record guarantees future returns, treat this as one input, not a decision.